When did Nektar Therapeutics (NKTR) last publish financial statements?

The last financial report for Nektar Therapeutics (NKTR) was published on 2025-05-09. Nektar Therapeutics (NKTR) reported financial results for 1 quarter 2025.

In which currency does Nektar Therapeutics (NKTR) publish its financial statements?

Nektar Therapeutics (NKTR) publishes the company’s financial results in USD.

What was the revenue for Nektar Therapeutics (NKTR) in 2024?

The revenue for Nektar Therapeutics (NKTR) in 2024 was 98.43M USD. You can see detailed financial data for Nektar Therapeutics (NKTR) in tables and graphs on this page.

What was the net profit for Nektar Therapeutics (NKTR) in the last year?

2025-03-14, Nektar Therapeutics (NKTR) reported a net profit of decreasing for the year 2024 at -56.91% compared to last year — reaching -118.96M USD. You can see detailed financial metrics for Nektar Therapeutics (NKTR) in tables and graphs on this page.

What was the revenue for Nektar Therapeutics (NKTR) in the last quarter?

The revenue for Nektar Therapeutics (NKTR) in the last quarter of 2025 was decreased at -51.66% year over year — reaching 10.46M USD.

What was the net profit for Nektar Therapeutics (NKTR) in the last quarter?

In the last quarter of the calendar (financial) year 2025, Nektar Therapeutics (NKTR) reported a net profit of increased at 38.26% year over year — reaching -50.88M USD.

What was the earnings per share (EPS) for Nektar Therapeutics (NKTR) in the last quarter?

The EPS (earnings per share) for Nektar Therapeutics (NKTR) in the last quarter of the calendar year 2024 was -8.68 USD per share, increasing by 497.18% year over year.

What is the net debt for Nektar Therapeutics (NKTR) at the moment?

The net debt for Nektar Therapeutics (NKTR) for the last period was increased at 10.9% year over year, amounting to -17.05M USD.

When is the publication date of the next report for Nektar Therapeutics (NKTR)?

The date of the next financial report for Nektar Therapeutics (NKTR) is 2025-08-07. You can follow corporate events for other companies in our events calendar.However, it is important to remember that Apple (AAPL) may publish financial reports at different times from year to year. Nonetheless, most companies have a consistent schedule for publishing earnings reports.Additionally, companies may change the dates of their report publications. Therefore, please verify the publication date. Some companies report not for the calendar year, but for the fiscal year. As a result, the years may differ.

Nektar Therapeutics

NASDAQ

NKTR

$58.50 2.88 5.18%

Today share price

About company

Company Description

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

USA

Sector: Healthcare Industry: Pharmaceuticals

Get access
to the rating of Finrange stocks

With this tariff you will be able to use the service without restrictions, all information will be available

Get 7 days free

Rating Finrange

Index: 28.75 %

Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

9.56M

EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

-7.49M

Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.61

Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

14.06M

YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

6190.32 %